Current Studies

Mild Cognitive Impairment due to Alzheimer’s disease

Name of Trial: (TANGO study)

A clinical research study to find out if the drug BII092 is safe and if it has the potential to be a helpful treatment that slows down disease progression in subjects with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD by comparing it to a placebo, and to find out more about BII092.

Who qualifies for the study?

You may qualify if:

You are between the ages of 50 to 80 years old, inclusive, at the time of consent.

You must have a gradual and progressive change in memory function over more than 6 months, reported by the subject and/or his/her informant/study partner.

You must have 1 informant/study partner who has frequent and sufficient contact with you (at least 10 hours/week) as to be able to provide accurate information about your cognitive and functional abilities. The study partner must agree to accompany the subject to clinic visits and/or be available by phone at designated times to provide information to site. Study partner must agree to monitor the patient’s administration of any prescribed medications.

Qualified participants may receive:

Study related physician’s care and close monitoring.

Study related medications, exams and blood tests.

Migraines

Name of Trial: (GAMMACORE study)

The purpose of this study is to evaluate the safety and effectiveness of a device called gammaCore Sapphire™ for the prevention of your migraine attacks.

Who qualifies for the study?

You may qualify if:

You are between the ages of 18 and 75 years old.

Been previously diagnosed with migraine.

You experience between 8 to 20 headache days per month (during the last 3 months), with at least 2 of them being migraine days during which the migraines last more than 4 hours.

Agrees to refrain from initiating or changing the type, dosage or frequency of any prophylactic medications.

Qualified participants may receive:

Study related physician’s care and close monitoring.

Study related medications, exams and blood tests.

Compensation for time and travel.

Multiple Sclerosis

Name of Trial: (ADAMAS study)

A clinical study to assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment.

Who qualifies for the study?

You may qualify if:

You are between the ages of 18 and 70, inclusive at screening.

Current medication regimen must be stable for at least 30 days prior to screening.

You have NOT received dalfampridine or amantadine within 30 days prior to screening.

Qualified participants may receive:

Study related physician’s care and close monitoring.

Study related medications, exams and blood tests.

Compensation for time and travel.

Name of Trial: (PASSAGE study)

A clinical study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy.

Who qualifies for the study?

You may qualify if:

Starting fingolimod at the time of study entry.

Qualified participants may receive:

Study related physician’s care and close monitoring.

Study related medications, exams and blood tests.

Compensation for time and travel.

Name of Trial: (EXCHANGE study)

The purpose of this study is to assess early phase safety and tolerability of converting patients from approved oral and injectable Relapsing Multiple Sclerosis (RMS) disease modifying therapies to Siponimod.

Who qualifies for the study?

You may qualify if:

You are between the ages of 18 and 65, inclusive at screening.

You have been diagnosed with advancing Relapsing Multiple Sclerosis with or without progressing features.

You do not have an active chronic disease other than Multiple sclerosis or have known immunodeficiency syndrome.

Qualified participants may receive:

Study related physician’s care and close monitoring.

Study related medications, exams and blood tests.

Epilepsy

Name of Trial: (PADSEVONIL Epilepsy study)

A clinical trial to evaluate the efficacy of the 3 selected dose regimens of PSL administered concomitantly up to 3 AED’s compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Who qualifies for the study?

You may qualify if:

You are 18 years of age or more.

You fulfill the diagnostic criteria for epilepsy and have observable focal-onset seizures of at least 3 years at the time of enrollment.

Qualified participants may receive:

Study related physician’s care and close monitoring.

Study related medications, exams and blood tests.